The modern role of radiation therapy in treating advanced-stage retinoblastoma: Long-term outcomes and racial differences

Amber Orman, Tulay Sengul, Feng Miao, Arnold Markoe, Joseph Panoff

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose/Objective(s) To evaluate the effects of various patient characteristics and radiation therapy treatment variables on outcomes in advanced-stage retinoblastoma.

Methods and Materials This was a retrospective review of 41 eyes of 30 patients treated with external beam radiation therapy between June 1, 1992, and March 31, 2012, with a median follow-up time of 133 months (11 years). Outcome measures included overall survival, progression-free survival, local control, eye preservation rate, and toxicity.

Results Over 90% of the eyes were stage V. Definitive external beam radiation therapy (EBRT) was delivered in 43.9% of eyes, adjuvant EBRT in 22% of eyes, and second-line/salvage EBRT in 34.1% of eyes. A relative lens sparing (RLS) technique was used in 68.3% of eyes and modified lens sparing (MLS) in 24.4% of eyes. Three eyes were treated with other techniques. Doses ≥45 Gy were used in 68.3% of eyes. Chemotherapy was a component of treatment in 53.7% of eyes. The 10-year overall survival was 87.7%, progression-free survival was 80.5%, and local control was 87.8%. White patients had significantly better overall survival than did African-American patients in univariate analysis (hazard ratio 0.09; 95% confidence interval 0.01-0.84; P=.035). Toxicity was seen in 68.3% of eyes, including 24.3% with isolated acute dermatitis.

Conclusions External beam radiation therapy continues to be an effective treatment modality for advanced retinoblastoma, achieving excellent long-term local control and survival with low rates of treatment-related toxicity and secondary malignancy.

Original languageEnglish
Pages (from-to)1037-1043
Number of pages7
JournalInternational Journal of Radiation Oncology Biology Physics
Volume90
Issue number5
DOIs
StatePublished - Jan 1 2014

Fingerprint

Retinoblastoma
radiation therapy
Radiotherapy
toxicity
Survival
Disease-Free Survival
progressions
dermatitis
lenses
Crystalline Lens
Dermatitis
Therapeutics
chemotherapy
African Americans
Lenses
hazards
confidence
therapy
Outcome Assessment (Health Care)
Confidence Intervals

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

The modern role of radiation therapy in treating advanced-stage retinoblastoma : Long-term outcomes and racial differences. / Orman, Amber; Sengul, Tulay; Miao, Feng; Markoe, Arnold; Panoff, Joseph.

In: International Journal of Radiation Oncology Biology Physics, Vol. 90, No. 5, 01.01.2014, p. 1037-1043.

Research output: Contribution to journalArticle

@article{11e3aa6a11c142cf896ac59d0e1cc546,
title = "The modern role of radiation therapy in treating advanced-stage retinoblastoma: Long-term outcomes and racial differences",
abstract = "Purpose/Objective(s) To evaluate the effects of various patient characteristics and radiation therapy treatment variables on outcomes in advanced-stage retinoblastoma.Methods and Materials This was a retrospective review of 41 eyes of 30 patients treated with external beam radiation therapy between June 1, 1992, and March 31, 2012, with a median follow-up time of 133 months (11 years). Outcome measures included overall survival, progression-free survival, local control, eye preservation rate, and toxicity.Results Over 90{\%} of the eyes were stage V. Definitive external beam radiation therapy (EBRT) was delivered in 43.9{\%} of eyes, adjuvant EBRT in 22{\%} of eyes, and second-line/salvage EBRT in 34.1{\%} of eyes. A relative lens sparing (RLS) technique was used in 68.3{\%} of eyes and modified lens sparing (MLS) in 24.4{\%} of eyes. Three eyes were treated with other techniques. Doses ≥45 Gy were used in 68.3{\%} of eyes. Chemotherapy was a component of treatment in 53.7{\%} of eyes. The 10-year overall survival was 87.7{\%}, progression-free survival was 80.5{\%}, and local control was 87.8{\%}. White patients had significantly better overall survival than did African-American patients in univariate analysis (hazard ratio 0.09; 95{\%} confidence interval 0.01-0.84; P=.035). Toxicity was seen in 68.3{\%} of eyes, including 24.3{\%} with isolated acute dermatitis.Conclusions External beam radiation therapy continues to be an effective treatment modality for advanced retinoblastoma, achieving excellent long-term local control and survival with low rates of treatment-related toxicity and secondary malignancy.",
author = "Amber Orman and Tulay Sengul and Feng Miao and Arnold Markoe and Joseph Panoff",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.ijrobp.2014.08.336",
language = "English",
volume = "90",
pages = "1037--1043",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - The modern role of radiation therapy in treating advanced-stage retinoblastoma

T2 - Long-term outcomes and racial differences

AU - Orman, Amber

AU - Sengul, Tulay

AU - Miao, Feng

AU - Markoe, Arnold

AU - Panoff, Joseph

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Purpose/Objective(s) To evaluate the effects of various patient characteristics and radiation therapy treatment variables on outcomes in advanced-stage retinoblastoma.Methods and Materials This was a retrospective review of 41 eyes of 30 patients treated with external beam radiation therapy between June 1, 1992, and March 31, 2012, with a median follow-up time of 133 months (11 years). Outcome measures included overall survival, progression-free survival, local control, eye preservation rate, and toxicity.Results Over 90% of the eyes were stage V. Definitive external beam radiation therapy (EBRT) was delivered in 43.9% of eyes, adjuvant EBRT in 22% of eyes, and second-line/salvage EBRT in 34.1% of eyes. A relative lens sparing (RLS) technique was used in 68.3% of eyes and modified lens sparing (MLS) in 24.4% of eyes. Three eyes were treated with other techniques. Doses ≥45 Gy were used in 68.3% of eyes. Chemotherapy was a component of treatment in 53.7% of eyes. The 10-year overall survival was 87.7%, progression-free survival was 80.5%, and local control was 87.8%. White patients had significantly better overall survival than did African-American patients in univariate analysis (hazard ratio 0.09; 95% confidence interval 0.01-0.84; P=.035). Toxicity was seen in 68.3% of eyes, including 24.3% with isolated acute dermatitis.Conclusions External beam radiation therapy continues to be an effective treatment modality for advanced retinoblastoma, achieving excellent long-term local control and survival with low rates of treatment-related toxicity and secondary malignancy.

AB - Purpose/Objective(s) To evaluate the effects of various patient characteristics and radiation therapy treatment variables on outcomes in advanced-stage retinoblastoma.Methods and Materials This was a retrospective review of 41 eyes of 30 patients treated with external beam radiation therapy between June 1, 1992, and March 31, 2012, with a median follow-up time of 133 months (11 years). Outcome measures included overall survival, progression-free survival, local control, eye preservation rate, and toxicity.Results Over 90% of the eyes were stage V. Definitive external beam radiation therapy (EBRT) was delivered in 43.9% of eyes, adjuvant EBRT in 22% of eyes, and second-line/salvage EBRT in 34.1% of eyes. A relative lens sparing (RLS) technique was used in 68.3% of eyes and modified lens sparing (MLS) in 24.4% of eyes. Three eyes were treated with other techniques. Doses ≥45 Gy were used in 68.3% of eyes. Chemotherapy was a component of treatment in 53.7% of eyes. The 10-year overall survival was 87.7%, progression-free survival was 80.5%, and local control was 87.8%. White patients had significantly better overall survival than did African-American patients in univariate analysis (hazard ratio 0.09; 95% confidence interval 0.01-0.84; P=.035). Toxicity was seen in 68.3% of eyes, including 24.3% with isolated acute dermatitis.Conclusions External beam radiation therapy continues to be an effective treatment modality for advanced retinoblastoma, achieving excellent long-term local control and survival with low rates of treatment-related toxicity and secondary malignancy.

UR - http://www.scopus.com/inward/record.url?scp=84920108962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920108962&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2014.08.336

DO - 10.1016/j.ijrobp.2014.08.336

M3 - Article

C2 - 25442037

AN - SCOPUS:84920108962

VL - 90

SP - 1037

EP - 1043

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -